Venlafaxine Hydrochloride

Introduction Overview

Generic Name

venlafaxine hydrochloride

Brand Name

Effexor

Dosage Form

tablets

Drug Class

Serotonin-norepinephrine reuptake inhibitors (SNRI)

Pharmacokinetics

Absorption:
Venlafaxine hydrochloride (Effexor) is well absorbed following oral administration, with at least 92% of a single dose absorbed as demonstrated through mass balance studies. Upon absorption, the drug undergoes extensive first-pass metabolism in the liver to its major active metabolite, O-desmethylvenlafaxine (ODV). Bioavailability from the tablet form is approximately 100% compared with oral solution, and food intake does not significantly affect absorption or the pharmacokinetics of venlafaxine or ODV. The peak plasma concentrations are usually attained within 2 to 4 hours post-dose for venlafaxine.

Distribution:
Venlafaxine exhibits moderate plasma protein binding, approximately 27% ± 2% across concentrations of 2.5 to 2215 ng/mL, while ODV shows about 30% ± 12% binding in the 100 to 500 ng/mL concentration range. Its moderate binding suggests minimal displacement interactions with other highly protein-bound drugs. The steady-state volume of distribution (Vd) for venlafaxine is about 7.5 ± 3.7 L/kg, and for ODV approximately 5.7 ± 1.8 L/kg, indicating extensive tissue distribution beyond plasma volume, consistent with the drug's lipophilicity and ability to penetrate various tissues including the central nervous system.

Metabolism:
Venlafaxine undergoes extensive hepatic metabolism primarily via the cytochrome P450 isoenzyme CYP2D6 to form O-desmethylvenlafaxine (ODV), which retains significant pharmacological activity. CYP3A4 plays a minor role in producing another less active metabolite, N-desmethylvenlafaxine. Genetic polymorphism in CYP2D6 can influence individual levels of venlafaxine and ODV; however, the total active moiety concentrations remain relatively consistent between poor and extensive metabolizers. Venlafaxine and its metabolites do not inhibit monoamine oxidase and have negligible affinity for muscarinic, histaminergic, or α1-adrenergic receptors, minimizing anticholinergic or sedative side effects.

Elimination:
The elimination of venlafaxine and its metabolites is predominantly renal. Approximately 87% of the administered dose is recovered in urine within 48 hours, consisting of 5% unchanged venlafaxine, 29% unconjugated ODV, 26% conjugated ODV, and 27% minor inactive metabolites. Venlafaxine exhibits linear pharmacokinetics across doses between 75 to 450 mg/day, with mean elimination half-lives of about 5 ± 2 hours for venlafaxine and 11 ± 2 hours for ODV. Steady-state plasma concentrations are achieved within 3 days of multiple dosing. Hepatic cirrhosis and renal impairment significantly prolong elimination half-lives and reduce clearance, necessitating dosage adjustments in these populations. In dialysis patients, elimination half-lives can be dramatically increased by up to 180% for venlafaxine and 142% for ODV, underscoring the importance of clinical monitoring and dosing modifications.

Dosage Forms

Available Dosage Forms:
Effexor is available as oral tablets formulated for systemic antidepressant therapy. These compressed tablets contain venlafaxine hydrochloride equivalent to 25 mg, 37.5 mg, 50 mg, 75 mg, or 100 mg of venlafaxine. The tablets have a characteristic peach/orange shield-shaped pentagonal form scored for ease of splitting into two pieces. Inactive ingredients include cellulose, lactose, magnesium stearate, sodium starch glycolate, and ferric oxide red for coloring.

Dosages for Adults and Adolescents:
The recommended initial dose for adult patients is 75 mg per day, administered in two or three divided doses with food to enhance tolerability. Based on clinical response and tolerability, doses may be increased to 150 mg/day and, if needed, further titrated up to a maximum of 375 mg/day using increments of up to 75 mg/day at intervals of no less than four days. Dosing beyond 225 mg/day may be considered for more severely depressed inpatient populations. For adolescents and pediatric patients, safety and efficacy have not been established, and Effexor is not approved for pediatric use; caution and clinical judgment are advised if deemed necessary.

Specific Patient Populations:
Dose adjustments are recommended for special populations based on altered pharmacokinetics. In patients with mild to moderate hepatic impairment (including cirrhosis), the total daily dose should be reduced by approximately 50%, and individualization of dosing may be necessary due to intersubject variability. For patients with mild to moderate renal impairment (glomerular filtration rate [GFR] 10–70 mL/min), a recommended dose reduction of 25% is advised, while patients on hemodialysis should have a 50% dose reduction. No routine dose adjustment is necessary solely based on gender or advanced age; however, elderly patients should be monitored carefully. Discontinuation of therapy requires gradual tapering to minimize withdrawal symptoms, with careful dose reduction rather than abrupt cessation.

Available Tablet Dosage Strengths:
- Oral tablet 25 mg (peach shield-shaped, scored)
- Oral tablet 37.5 mg (peach shield-shaped, scored)
- Oral tablet 50 mg (peach shield-shaped, scored)
- Oral tablet 75 mg (peach shield-shaped, scored)
- Oral tablet 100 mg (peach shield-shaped, scored)

These dosage strengths facilitate flexible dosing regimens tailored to individual patient needs and tolerability.

Mechanism Of Action

Venlafaxine hydrochloride, the active component of Effexor, exerts its antidepressant effects primarily through inhibition of the reuptake of two key neurotransmitters in the central nervous system—serotonin (5-HT) and norepinephrine (NE). By selectively blocking the serotonin transporter (SERT) and norepinephrine transporter (NET), venlafaxine increases the synaptic availability of these monoamines, enhancing neurotransmission and contributing to mood elevation and alleviation of depressive symptoms. At lower doses, venlafaxine more potently inhibits serotonin reuptake, whereas at higher doses norepinephrine reuptake inhibition becomes increasingly significant, which may contribute to augmented clinical efficacy in certain patients with major depressive disorder.

In addition, venlafaxine and its active metabolite, O-desmethylvenlafaxine (ODV), exhibit weak inhibition of dopamine reuptake, although this action is minor and is not considered a primary contributor to its therapeutic effects. Importantly, neither venlafaxine nor ODV demonstrate significant affinity for muscarinic cholinergic, histaminergic, or α1-adrenergic receptors, nor do they possess monoamine oxidase (MAO) inhibitory activity. This receptor selectivity profile minimizes anticholinergic side effects, sedation, and cardiovascular adverse effects often encountered with other psychotropic agents.

At the cellular level, enhanced serotonergic and noradrenergic neurotransmission modulates multiple postsynaptic receptor systems and downstream intracellular signaling pathways implicated in neuroplasticity, stress response, and mood regulation. This leads to restoration of synaptic connectivity and neuronal health disrupted in depressive states. Clinical and preclinical data suggest that these neuroadaptive changes underpin the delayed onset of antidepressant efficacy typically observed with venlafaxine and related agents.

Comparatively, venlafaxine shares the dual reuptake inhibitory mechanism with other serotonin-norepinephrine reuptake inhibitors (SNRIs) but differs from selective serotonin reuptake inhibitors (SSRIs) which predominantly affect serotonin neurotransmission. This broader action may be beneficial in treating a spectrum of depressive symptoms and comorbid conditions such as anxiety disorders. Clinical trials have demonstrated the efficacy of venlafaxine across a range of doses, consistent with its dose-related neurotransmitter effects. Current research also explores venlafaxine’s impact on neurotrophic factors and inflammatory mediators, further elucidating its complex mechanism of antidepressant action.

Pharmacological Actions

Inhibition of serotonin (5-HT) reuptake, increasing serotonergic neurotransmission.
Inhibition of norepinephrine (NE) reuptake, enhancing noradrenergic signaling.
Weak inhibition of dopamine reuptake, contributing minimally to pharmacological profile.
Potentiation of neurotransmitter activity in the central nervous system leading to mood elevation.
Lack of significant affinity for muscarinic, histaminergic, or α1-adrenergic receptors, resulting in a reduced risk of anticholinergic or sedative side effects.
No monoamine oxidase (MAO) inhibitory activity, reducing risk of MAOI-related adverse interactions.
Dose-dependent reuptake inhibition, with serotonin predominance at lower doses and increasing norepinephrine effect at higher doses.
Neuroplasticity enhancing effects via modulation of intracellular signaling cascades and receptor systems.
Improvement of depression-related symptoms including mood, energy, and cognitive function.
Anxiolytic properties supporting its use in anxiety disorders in extended-release formulations.

Therapeutic Or Clinical Uses

Treatment of major depressive disorder (MDD) in adults.
Management of depressive episodes characterized by persistent depressed or dysphoric mood interfering with normal functioning.
Maintenance therapy to prevent recurrence of depressive episodes in patients who have responded to acute treatment.
Off-label use considerations in anxiety and other neuropsychiatric conditions with clinical judgment.
Utilization in patients who may benefit from combined serotonergic and noradrenergic antidepressant effects.
Therapeutic option when selective serotonin reuptake inhibitors (SSRIs) are ineffective or not tolerated.
Potential benefit for patients with comorbid anxiety symptoms linked to depression.
Not approved for use in pediatric populations; monitoring and evaluation of risk versus benefit is necessary if prescribed.
Therapeutic benefit demonstrated in both outpatient and inpatient settings for varied severity of major depression.

Side Or Adverse Effects

Common gastrointestinal effects: nausea (up to 37-58%), vomiting, constipation, and anorexia.
Central nervous system symptoms: headache, dizziness, somnolence, insomnia, nervousness, anxiety, tremor, and blurred vision.
Cardiovascular effects: sustained hypertension, tachycardia, vasodilation, postural hypotension.
Sexual dysfunction including abnormal ejaculation/orgasm and impotence in men.
Dry mouth and sweating noted with increased frequency compared to placebo.
Withdrawal symptoms upon abrupt discontinuation including agitation, dizziness, sensory disturbances such as electric shock sensations, and nausea.
Potential for hyponatremia, particularly in elderly patients or those on diuretics, associated with syndrome of inappropriate antidiuretic hormone secretion (SIADH).
Rare but serious reactions: serotonin syndrome, neuroleptic malignant syndrome-like reactions, interstitial lung disease, eosinophilic pneumonia, and elevated risk of bleeding especially when combined with anticoagulants or NSAIDs.
Elevated serum cholesterol concentrations during prolonged therapy.
Seizures reported rarely; use cautiously in patients with seizure history.
Allergic reactions such as rash, hives, and angioedema.
Possible worsening of depression or emergence of suicidal ideation especially during initial treatment or dose changes.
Mydriasis, with caution advised in patients susceptible to angle-closure glaucoma.
Postmarketing reports of cardiac arrhythmias including QT prolongation and torsade de pointes.
Weight loss and decreased appetite, particularly noted in pediatric populations.

Precautions

Risk of clinical worsening and emergence of suicidality, especially in children, adolescents, and young adults; necessitates close monitoring.
Gradual tapering recommended to avoid discontinuation symptoms.
Screen patients for bipolar disorder before initiating treatment due to risk of manic switch.
Regular blood pressure monitoring due to potential for sustained hypertension.
Use with caution in patients with pre-existing hypertension or cardiovascular disease.
Monitor for signs of serotonin syndrome, especially if combined with other serotonergic drugs.
Avoid concomitant use with monoamine oxidase inhibitors (MAOIs).
Careful use in hepatic and renal impairment with appropriate dose adjustments.
Consider potential interactions with CNS-active drugs and drugs affecting cytochrome P450 enzymes.
Caution advised in elderly due to increased risk of hyponatremia and possible sensitivity.
Advise patients to avoid abrupt cessation, alcohol consumption, and report any new or worsening symptoms.
Closely observe for abnormal bleeding, especially when used with anticoagulants or NSAIDs.
Monitor growth parameters and weight in pediatric patients if used off-label.
Use caution in patients with seizure disorders; discontinue if seizures occur.
Educate patients about potential sexual side effects and other adverse reactions.

Warnings

Increased risk of suicidal ideation and behavior in children, adolescents, and young adults during early treatment phases.
Not approved for pediatric use; efficacy and safety not established.
Serotonin syndrome can be life-threatening, especially with concurrent serotonergic agents or MAOIs.
Concomitant use with MAOIs is contraindicated; allow proper washout periods before switching.
Risk of sustained hypertension; monitor blood pressure regularly during treatment.
May cause mydriasis; caution in patients at risk of angle-closure glaucoma.
Potential for clinical worsening of depression, including emergence of anxiety, agitation, mania, or hostility.
Abrupt discontinuation can cause significant withdrawal symptoms; taper dose carefully.
Cases of hyponatremia leading to serious complications, especially in elderly.
Possible cardiovascular adverse events including QT prolongation and arrhythmias.
Warn about the risk of abnormal bleeding with concurrent use of anticoagulants or antiplatelet drugs.
Use cautiously in patients with concomitant systemic illnesses affecting metabolism or hemodynamics.
Pregnancy Category C; advise of potential neonatal complications if exposure occurs during late pregnancy.
Careful assessment needed when prescribing for patients with history of seizures or mania.

Contraindication

Hypersensitivity to venlafaxine hydrochloride or any component of the formulation.
Concurrent administration with monoamine oxidase inhibitors (MAOIs) or use within 14 days of stopping MAOIs.
Use of MAOIs within at least 7 days of stopping Effexor due to risk of serious or fatal drug interactions.
Concomitant use with pimozide due to risk of QT prolongation and cardiac arrhythmias.
Known hypersensitivity to any excipients of the tablet formulation.
Not approved for use in pediatric patients for major depressive disorder.
Any use contraindicated in combination with other serotonergic or neuroleptic malignant syndrome-inducing drugs without careful monitoring.

Drug Interactions

Concomitant use with MAOIs is contraindicated due to risk of serotonin syndrome.
Potential increased plasma concentrations when coadministered with cimetidine due to inhibition of venlafaxine first-pass metabolism; caution advised in hypertensive, elderly, or hepatic impaired patients.
No significant pharmacokinetic effects when coadministered with diazepam or lithium.
Venlafaxine increases plasma concentrations of haloperidol and risperidone by inhibiting CYP2D6 metabolism; monitor for enhanced drug effects or toxicity.
Metoprolol plasma levels increased 30-40% when coadministered with venlafaxine; venlafaxine may reduce blood pressure-lowering effect of metoprolol.
Concomitant use with drugs that impair platelet aggregation (NSAIDs, aspirin, warfarin) increases bleeding risk.
CYP2D6 inhibitors may alter the balance of venlafaxine and ODV concentrations but do not require dosage adjustment.
Ketoconazole and other CYP3A4 inhibitors can increase venlafaxine and ODV levels; monitor patients for side effects.
Concomitant use with other serotonergic agents (SSRIs, SNRIs, triptans, tramadol, St. John's Wort, tryptophan) increases risk of serotonin syndrome.
Venlafaxine does not inhibit CYP3A4, CYP1A2, CYP2C9, or CYP2C19 significantly; minimal interaction with substrates of these enzymes.
Indinavir plasma concentrations reduced when coadministered with venlafaxine; clinical significance unknown.
Caution advised with CNS-active drugs due to potential additive effects or unknown interactions.
Venlafaxine is not highly protein bound; unlikely to displace other protein-bound drugs significantly.
Avoid concomitant use with serotonin precursors due to risk of serotonin syndrome.

Preparations Of The Drug

Effexor tablets containing venlafaxine hydrochloride equivalent to 25 mg, peach, shield-shaped, pentagonal, scored, with imprint '25 W 701'.
Effexor tablets containing venlafaxine hydrochloride equivalent to 37.5 mg, peach, shield-shaped, pentagonal, scored, with imprint '375 W 781'.
Effexor tablets containing venlafaxine hydrochloride equivalent to 50 mg, peach, shield-shaped, pentagonal, scored, with imprint '50 W 703'.
Effexor tablets containing venlafaxine hydrochloride equivalent to 75 mg, peach, shield-shaped, pentagonal, scored, with imprint '75 W 704'.
Effexor tablets containing venlafaxine hydrochloride equivalent to 100 mg, peach, shield-shaped, pentagonal, scored, with imprint '100 W 705'.
Inactive ingredients in all tablet formulations include cellulose, lactose, magnesium stearate, sodium starch glycolate type A (potato), and ferric oxide red.
Tablets are dispensed in bottles (20 to 60 count) with well-closed containers to protect against moisture.
Storage at controlled room temperature between 20° to 25°C (68° to 77°F) in a dry place is recommended.
The unit of use packaging is intended to be dispensed as a whole unit to ensure patient compliance and safety.
Each packaged tablet includes a Medication Guide to inform patients of risks and proper use.